Suchen
Vir Biotechnology Inc
VIRZur Watchlist hinzufügen
10.600USD
-0.320-2.93%
Handelsschluss 09-18 16:00（ET）
1.79BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Vir Biotechnology Inc Unternehmen
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Vir Biotechnology Inc Profil
BörsenkürzelVIR
Name des UnternehmensVir Biotechnology Inc
IPO-datumOct 11, 2019
CEODe Backer (Marianne)
Anzahl der mitarbeiter408
WertpapierartOrdinary Share
GeschäftsjahresendeOct 11
Addresse1800 Owens Street
StadtSAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94158
Telefon14159064324
Websitehttps://www.vir.bio/
BörsenkürzelVIR
IPO-datumOct 11, 2019
CEODe Backer (Marianne)
Führungskräfte von Vir Biotechnology Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
233.10K
-15.93%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
233.10K
-15.93%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
233.10K
-15.93%
Mr. Brent Sabatini, CPA
Mr. Brent Sabatini, CPA
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
57.44K
-0.66%
Mr. Brent Sabatini, CPA
Mr. Brent Sabatini, CPA
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
57.44K
-0.66%
Mr. Brent Sabatini, CPA
Mr. Brent Sabatini, CPA
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
57.44K
-0.66%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-24.50%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-24.50%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-24.50%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Chairman of the Board
Independent Chairman of the Board
31.81K
+25.15%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
233.10K
-15.93%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
233.10K
-15.93%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
233.10K
-15.93%
Mr. Brent Sabatini, CPA
Mr. Brent Sabatini, CPA
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
57.44K
-0.66%
Mr. Brent Sabatini, CPA
Mr. Brent Sabatini, CPA
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
57.44K
-0.66%
Mr. Brent Sabatini, CPA
Mr. Brent Sabatini, CPA
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
Interim Principal Financial Officer, Senior Vice President, Chief Accounting Officer
57.44K
-0.66%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Vir Biotechnology Inc?
Die fünf größten Anteilseigner von Vir Biotechnology Inc sind: Dr. Marianne De Backer, Ph.D.
Wie viele Institutionen halten Anteile an Vir Biotechnology Inc (VIR)?
Mit Stand vom 2026Q1 halten 497 Institutionen Anteile an Vir Biotechnology Inc, mit einem Gesamtmarktwert von etwa 130.35M, was 77.29% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 9591956.00 gestiegen.